Advertisement
UK markets closed
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.35
    +1.45 (+1.77%)
     
  • GOLD FUTURES

    2,335.90
    -10.50 (-0.45%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,191.66
    -195.46 (-0.37%)
     
  • CMC Crypto 200

    1,427.60
    +12.84 (+0.91%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Why Novavax Stock Eked Out a Gain Today

The coronavirus might not pose the threat it once was, and Novavax (NASDAQ: NVAX) can be considered a laggard in the Great COVID-19 Vaccine Race, but the stock certainly has plenty of believers. The more important of these two filings was with the U.S. Food and Drug Administration (FDA). Novavax's money product of the moment, its coronavirus vaccine Nuvaxovid, won emergency use authorization (EUA) from the American regulator last month.